For example, the claim generated by LLaMA 3.3 70B (API) that ‘dulaglutide is an effective and safe treatment option for improving glycaemic control in youths with type 2 diabetes’ (OSF ID 76) implies much broader efficacy and safety than the original text, which concluded: ‘dulaglutide at a once-weekly dose of 0.75 or 1.5 mg was superior to placebo in improving glycaemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI’. Here, INS is linked to type 2 diabetes mellitus.